Edition:
United States

TherapeuticsMD Inc (TXMD.A)

TXMD.A on American Stock Exchange

4.94USD
4:00pm EDT
Change (% chg)

$-0.16 (-3.04%)
Prev Close
$5.09
Open
$5.01
Day's High
$5.01
Day's Low
$4.93
Volume
5,802
Avg. Vol
--
52-wk High
$5.21
52-wk Low
$4.55

Chart for

About

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials... (more)

Overall

Beta: 0.93
Market Cap(Mil.): $1,103.78
Shares Outstanding(Mil.): 216.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

BRIEF-TherapeuticsMD phase 3 topline data NDA submission for TX-004HR expected in Q4 2017

* Phase 3 topline data NDA submission for TX-004HR expected in Q4 2017 Source text: (http://bit.ly/2yX9sek) Further company coverage:

Oct 04 2017

BRIEF-TherapeuticsMD prices offering of 12.4 mln shares at $5.65 per share

* TherapeuticsMD - Announced pricing of an underwritten public offering of 12.4 million shares of its common stock at a price to public of $5.65 per share Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-TherapeuticsMD announces public offering of 12.4 mln shares of common stock

* TherapeuticsMD announces public offering of 12.4 million shares of common stock Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-‍TherapeuticsMD announces submission of additional endometrial safety information to new drug application for TX-004HR​

* ‍TherapeuticsMD announces submission of additional endometrial safety information to new drug application for TX-004HR​

Sep 14 2017

BRIEF-TherapeuticsMD provides TX-004HR regulatory update

* TherapeuticsMD Inc - announced a regulatory update regarding new drug application (NDA) for TX-004HR

Aug 10 2017

BRIEF-TherapeuticsMD • Q2 loss per share $0.10

* TherapeuticsMD announces second quarter 2017 financial results

Aug 03 2017

BRIEF-TherapeuticsMD provides TX-004HR regulatory update

* TherapeuticsMD- ‍received minutes of meeting, per FDA's request, has formally submitted new information for consideration related to nda for TX-004HR​

Jul 17 2017

UPDATE 1-FDA rejects TherapeuticsMD's vaginal pain drug; shares slump

May 8 Women's healthcare company TherapeuticsMD Inc said the U.S. Food and Drug Administration had rejected its application to market its drug to treat vaginal pain, sending its shares down about 13 percent in premarket trading on Monday.

May 08 2017

FDA rejects TherapeuticsMD's vaginal pain drug

May 8 Women's healthcare company TherapeuticsMD Inc said on Monday the U.S. Food and Drug Administration had rejected the drug developer's application to market its drug to treat vaginal pain.

May 08 2017

BRIEF-TherapeuticsMD receives complete response letter from FDA for TX-004hr NDA

* Therapeuticsmd receives complete response letter from fda for tx-004hr new drug application

May 08 2017

Earnings vs. Estimates